Wedbush analyst, Liana Moussatos, cut her price target on BioMarin Pharma (NASDAQ: BMRN) as the top line beat on Aldurazyme ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE